Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01933906 | Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response | completed | Phase 1 | 12 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT02240719 | Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer | completed | Phase 1 | 20 | University of California, DavisOTHER | 1 | Jan 4, 2019 |
| clinicaltrials |
| NCT01292603 | A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 240 | Hoffmann-La RocheINDUSTRY | 19 | Dec 19, 2018 | clinicaltrials |
| NCT02070458 | Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 13, 2018 | clinicaltrials |
| NCT00840346 | Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)(PANOBIDARA) | completed | Phase 1 / Phase 2 | 46 | PETHEMA FoundationOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT01051063 | Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy | completed | Phase 1 | 17 | GlaxoSmithKlineINDUSTRY | 3 | Nov 29, 2018 | clinicaltrials |
| NCT00295932 | Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 79 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT00075010 | Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00047502 | Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia | completed | Phase 1 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT00002831 | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia | completed | Phase 1 / Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 26, 2018 | clinicaltrials |
| NCT00005092 | Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 1 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 26, 2018 | clinicaltrials |
| NCT00003693 | Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | completed | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 25, 2018 | clinicaltrials |
| NCT01342289 | Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | completed | Phase 1 | 127 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT01202877 | PKC412 and 5-Azacytidine | completed | Phase 1 / Phase 2 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02264873 | Phase I, Dose Escalation Study of Decitabine | completed | Phase 1 | 3 | University of FloridaOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT01734304 | DC Vaccination for Postremission Therapy in AML | completed | Phase 1 / Phase 2 | 13 | Ludwig-Maximilians - University of MunichOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT01621724 | WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study | completed | Phase 1 / Phase 2 | 7 | Cell Medica LtdINDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT02550535 | A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients | completed | Phase 1 / Phase 2 | 3 | Cell Medica LtdINDUSTRY | 3 | Oct 2, 2018 | clinicaltrials |
| NCT00352001 | Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 37 | Mikkael Sekeres MDOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01319864 | POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients | completed | Phase 1 | 20 | Seattle Children's HospitalOTHER | 2 | Sep 7, 2018 | clinicaltrials |
| NCT01422603 | Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | completed | Phase 1 / Phase 2 | 9 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT01602952 | Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI | completed | Phase 1 / Phase 2 | 85 | Il-Yang Pharm. Co., Ltd.INDUSTRY | 3 | Aug 29, 2018 | clinicaltrials |
| NCT00542971 | Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) | completed | Phase 1 / Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT01534260 | Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype | completed | Phase 1 / Phase 2 | 37 | Hamid SayarOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT00295841 | Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | completed | Phase 1 | 53 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00725283 | Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 34 | GlaxoSmithKlineINDUSTRY | 2 | Aug 7, 2018 | clinicaltrials |
| NCT01662505 | Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 19 | Boehringer IngelheimINDUSTRY | 1 | Jul 30, 2018 | clinicaltrials |
| NCT01971476 | Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known | completed | Phase 1 | 22 | Boehringer IngelheimINDUSTRY | 5 | Jul 30, 2018 | clinicaltrials |
| NCT02201329 | Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | completed | Phase 1 | 5 | Boehringer IngelheimINDUSTRY | 1 | Jul 30, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00001830 | Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | completed | Phase 1 | 110 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01445132 | Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation | completed | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01517035 | Improving Blood Stem Cell Collection and Transplant Procedures | completed | Phase 1 / Phase 2 | 43 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02226861 | Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation | completed | Phase 1 | 24 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01768897 | CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 67 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT01352650 | Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) | completed | Phase 1 | 71 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02345382 | Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia | completed | Phase 1 | 42 | BayerINDUSTRY | 2 | Jun 25, 2018 | clinicaltrials |
| NCT00890929 | Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 45 | Stanford UniversityOTHER | 1 | Jun 18, 2018 | clinicaltrials |
| NCT01129193 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | completed | Phase 1 | 44 | Amir MortazaviOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02210858 | Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders | completed | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02203825 | Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | completed | Phase 1 | 12 | Celyad Oncology SAINDUSTRY | 1 | Jun 1, 2018 | clinicaltrials |
| NCT00504972 | Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies | completed | Phase 1 | 23 | Weill Medical College of Cornell UniversityOTHER | 1 | May 29, 2018 | clinicaltrials |
| NCT00660920 | Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies | completed | Phase 1 | 81 | Ariad PharmaceuticalsINDUSTRY | 1 | May 16, 2018 | clinicaltrials |
| NCT01558167 | A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia(CLL2P) | completed | Phase 1 / Phase 2 | 22 | German CLL Study GroupOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT02326584 | A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML | completed | Phase 1 | 116 | Seagen Inc.INDUSTRY | 1 | May 9, 2018 | clinicaltrials |
| NCT00952237 | Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF | completed | Phase 1 | 13 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT00963274 | Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 1 | 18 | Virginia Commonwealth UniversityOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT01567709 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2018 | clinicaltrials |
| NCT01030536 | Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) | completed | Phase 1 / Phase 2 | 23 | MedImmune LLCINDUSTRY | 2 | Apr 9, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jan 4, 2019source: clinicaltrials